- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04851678
Longitudinal Impact of Stressors in Adults With Tourette Syndrome (LISA-TS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tourette syndrome (TS) is a widely prevalent neurodevelopmental disorder with limited treatment options,(1,2) substantial impact on quality of life in children(3-7) and adults,(4,8-10) and two-fold increased risk of premature death.(11,12) Tics are the defining feature of TS, and as a result, TS is often narrowly perceived in terms of tics alone. Tics themselves tend to wane in late adolescence, with distressing tics persisting in only one-third of TS patients.(13) Because tics generally diminish with age, the plight of adults with TS is often neglected. Over half of TS adults suffer from anxiety and depression,(10,14) and a similar percentage experience symptoms of attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), findings recently corroborated in our own clinical population.(10) Many TS adults struggle to form meaningful relationships with peers, and one-third feel inadequately supported by their families.(13) The burden of TS in adulthood extends beyond mental and social health. In a national registry cohort study, individuals with TS had a mortality rate ratio of 1.8 relative to healthy controls, even after controlling for comorbid psychiatric diagnoses.(11) The causes of more frequent premature death in TS populations are unclear, with many mechanisms implicated, including suicide,(15) traumatic accidents,(12) substance abuse,(16) metabolic disorders,(12,17) and complications from pharmacotherapy.(18,19)
Environmental stressors are also postulated to impact the course of TS.(20) An environmental stressor is any external condition or event that poses a threat to an individual's well-being.(21) Such stressors are known to alter brain development(22-24) and increase risk of adulthood psychopathology.(25,26) A single study has explored the role of environmental stressors in TS, finding that selected stressors predicted two-year tic and psychiatric symptom severity in a pediatric cohort (n=37 patients).(27) No similar investigations have been undertaken in TS adults. The Investigators hypothesize that environmental stressors are risk factors for more severe adult TS phenotype. The Investigators propose a two-year, longitudinal pilot study of TS adults (>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL).
Aim 1. Determine influence of lifetime environmental stressors on tic severity in TS adults. Hypothesis: Number of lifetime stressors at baseline assessment is associated with greater tic severity at two year follow-up. Seventy adults with TS will be recruited from the Vanderbilt TS Clinic to complete a baseline assessment, consisting of validated clinical rating scales for tic severity (Yale Global Tic Severity Scale), common psychiatric comorbidities, and lifetime environmental stressors (Stress and Adversity Inventory for Adults, STRAIN). Because acute and chronic stressors exert differential physiologic and clinical-level effects,(28-31) the STRAIN assesses these separately. The Investigators will use multivariable linear regression to examine the influence of acute and chronic lifetime stressor count at baseline on tic severity at two years, controlling for baseline tic severity and psychiatric comorbidities, as well as anti-tic medications at follow-up. Results will clarify the impact of environmental stressors on tic severity in TS adults.
Aim 2. Determine influence of lifetime environmental stressors on depression in TS adults.
Hypothesis: Number of lifetime stressors at baseline assessment is associated with more depressive symptoms at two-year follow-up. Depression is the psychiatric symptom that most impacts adult functioning and QOL.(10) As part of baseline and follow-up assessments, Aim 1 participants will complete standardized, semi-structured psychiatric interviews (Mini International Neuropsychiatric Interview, MINI) and validated self-report depression scales (NeuroQOL-Depression). The statistical approach from Aim 1 will be adopted to examine the influence of acute and chronic lifetime stressor count at baseline on depression symptom severity at two years, again controlling for select confounds. Findings will delineate the effects of acute and chronic environmental stressors on depression in adults with TS.
Aim 3. Determine influence of positive childhood experiences on health-related quality of life (HRQOL) in TS adults. Hypothesis: Greater number of positive childhood experiences is associated with better HRQOL in TS adults at two-year follow-up. Positive childhood experiences partially mitigate the negative effects of adverse childhood experiences.(32) At baseline and follow-up visits, Aim 1 participants will report number and type of positive childhood experiences. They will also complete a validated HRQOL measure specific to TS: the Gilles de la Tourette-Quality of Life Scale (GTS-QOL). The Investigators will use multivariable regression modeling to examine the influence of positive childhood experiences on future HRQOL, controlling for environmental stressors and baseline HRQOL. Results will elucidate the potentially moderating role of positive childhood experiences on HRQOL in TS adults.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michelle Eckland, BS
- Phone Number: 615-875-7394
- Email: michelle.r.eckland.1@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-5400
- Recruiting
- Vanderbilt University Medical Center
-
Contact:
- Michelle Eckland, BS
- Phone Number: 615-936-2025
- Email: michelle.r.eckland.1@vumc.org
-
Principal Investigator:
- David Isaacs, MD, MPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- adults (>18) meeting Diagnostic and Statistics Manual, 5th edition (DSM-V) criteria for Tourette syndrome, chronic motor tic disorder, or chronic vocal tic disorder
- ability to provide informed consent
- English proficiency
Exclusion Criteria:
- significant medical, neurologic, or psychiatric diagnoses (e.g. uncontrolled epilepsy, chronic heart failure, schizophrenia) besides TS and its commonly co-occurring psychiatric diagnoses
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Individuals with Tourette syndrome (TS)
Individuals previously diagnosed with Tourette syndrome (TS).
Participants must be 18 years of age or older.
|
None - observational study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Tic Score from Yale Global Tic Severity Scale (YGTSS)
Time Frame: 2 years post-baseline assessment
|
Semi-structured, clinician-administered interview to assess tic severity.
Total tic scores are a composite of motor tic scores (0-25) and phonic tic scores (0-25) based on 5 dimensions of tic severity: number, frequency, intensity, complexity, and interference.
Total tic scores range from 0-50.
Higher scores indicate great tic severity.
The YGTSS is the gold-standard clinical rating scale for tic severity.
|
2 years post-baseline assessment
|
NeuroQOL-Depression Score
Time Frame: 2 years post-baseline assessment
|
NeuroQOL-Depression is a validated, 8-item self-report scale assessing symptoms of depression.
Raw total scores range from 8-40; raw scores are converted to T-scores based on normative samples.
Higher scores indicate more depressive symptoms.
NeuroQOL-Depression is part of the Neuro-QOL (Quality of Life in Neurological Disorders) measurement system.
The scale is designed to be completed with one minute.
|
2 years post-baseline assessment
|
Gilles de la Tourette Quality of Life Scale (GTS-QOL) Score
Time Frame: 2 years post-baseline assessment
|
The GTS-QOL is a 27-item self-report scale.
Respondents rate each item on a Likert scale ranging from 0 ("no problem") to 4 ("extreme problem").
The scale is composed of four sub-scales: Psychological (11 items), Physical/Activities of Daily Living (Physical/ADL) (7 items), Obsessive-Compulsive (OC) (5 items), and Cognitive (4 items) (39).
Item scores within each subscale are summed and then normalized to 100 to generate the subscale score.
The four subscale scores are then summed and normalized to 100 to yield the total score.
Higher scores indicate worse health-related quality of life.
|
2 years post-baseline assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NeuroQOL-Anxiety Score
Time Frame: 2 years post-baseline assessment
|
NeuroQOL-Depression is a validated, 8-item self-report scale assessing symptoms of anxiety.
Raw total scores range from 8-40; raw scores are converted to T-scores based on normative samples.
Higher scores indicate more anxiety symptoms.
NeuroQOL-Anxiety is part of the Neuro-QOL (Quality of Life in Neurological Disorders) measurement system.
The scale is designed to be completed with one minute.
|
2 years post-baseline assessment
|
Adult ADHD Self-Report Screening Scale for DSM-V (ASRS-V) Score
Time Frame: 2 years post-baseline assessment
|
ASRS-V is a 6-question scale screening for symptoms of inattention and hyperactivity.
Each item is rated 0 ("never") to 4 ("very often").
Total score is the sum of individual item scores.
Higher score indicates more ADHD symptoms.
In clinical populations, ASRS-V total score cutoff ≥ 14 is 81% sensitive and 70% specific for detecting ADHD.
|
2 years post-baseline assessment
|
Dimensional Obsessive-Compulsive Scale (DOCS) Score
Time Frame: 2 years post-baseline assessment
|
DOCS is a 20-item, validated self-report scale assessing for severity of obsessive-compulsive symptoms.
Total score ranges from 0-80, with higher scores indicating more OCD symptoms.
In clinical populations, DOCS total score cutoff ≥ 21 is 70% sensitive and 70% specific in distinguishing OCD from other anxiety disorders.
|
2 years post-baseline assessment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David A Isaacs, MD, MPH, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Disease
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Neurodevelopmental Disorders
- Tic Disorders
- Syndrome
- Tourette Syndrome
Other Study ID Numbers
- U12134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tourette Syndrome
-
Children's Hospital Medical Center, CincinnatiTourette Association of AmericaRecruitingTourette Syndrome | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tourette Syndrome, Modifier ofUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ministry of Health, ItalyCompletedTourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette SyndromeItaly
-
Tasly Pharmaceuticals, Inc.Not yet recruitingTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States
-
Emalex Biosciences Inc.CompletedTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States, Poland, France, Canada, Germany
-
Vanderbilt University Medical CenterCompletedTourette Syndrome | Tourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States
-
Johns Hopkins UniversityCompletedTourette Syndrome in Children | Tourette Syndrome in Adolescence | Habit Reversal Training | TicUnited States
-
Tel Aviv Medical CenterUnknownTourette Syndrome in Children | Tourette Syndrome in Adolescence | Chronic Tic DisorderIsrael
-
Wake Forest University Health SciencesUniversity of Rochester; Tourette Association of AmericaRecruitingTourette Syndrome | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tic Disorder, ChildhoodUnited States
-
University of MinnesotaCompletedTourette Syndrome | Tic Disorders | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tic Disorder, Childhood | Tic, MotorUnited States
-
Max Planck Institute for Human Cognitive and Brain...Hannover Medical School; Leipzig University Medical CenterCompletedTourette Syndrome | Gilles de la Tourette SyndromeGermany
Clinical Trials on None - observational study
-
Taysha Gene Therapies, Inc.Withdrawn
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
AstraZenecaRecruiting
-
University of ExeterRecruiting
-
Major Extremity Trauma Research ConsortiumRecruiting
-
Medialis Ltd.Metabolic Support UKCompletedX-linked Hypophosphatemia (XLH)United Kingdom
-
PfizerCompletedTransthyretin Amyloidosis | Transthyretin Gene MutationsUnited States, France, Spain, Taiwan, Israel, Korea, Republic of, Denmark, Canada, Netherlands, Japan, Sweden, Brazil, Mexico, Argentina, Portugal, Belgium, Bulgaria, Cyprus, Germany, Italy, Malaysia, Romania, Saudi Arabia, Turkey, United...
-
German Cancer Research CenterActive, not recruitingCancer-related FatigueGermany
-
UNC Lineberger Comprehensive Cancer CenterAmerican Cancer Society, Inc.Completed